Harmony Biosciences CFO Disposes $139K in Stock Amid Strong WAKIX Sales and Clinical Updates
Harmony Biosciences Holdings' Chief Financial Officer, Sandip Kapadia, sold 3,746 shares on January 26, 2026, for $139,171 under a Rule 10b5-1 trading plan. The company reported preliminary unaudited WAKIX net product revenue of roughly $243 million for Q4 2025 and $868 million for the full year, a 21% increase versus 2024, and issued a 2026 WAKIX …